title: Alterations in lipoprotein profiles in dogs with lymphoma.
abstract: After a 12-hour fast, blood samples were obtained from 31 dogs with previously untreated lymphoma. Blood samples were also collected from 16 of these dogs after up to 5 treatments with doxorubicin (30 mg/m2 intravenously every 3 weeks). All 16 dogs underwent complete remission. Five dogs were re-evaluated after relapse and after overt signs of cancer cachexia had become clinically apparent. Samples were assayed for 8 quantitative parameters: total cholesterol (T-CH) and total triglyceride (T-TG) concentrations, and the concentration of cholesterol and triglyceride in each of the three major lipoprotein fractions, very-low-density lipoprotein (LDL-CH and LDL-TG), and high-density lipoprotein (HDL-CH and HDL-TG). The results were compared with those from 20 healthy control dogs of similar weight and age before and 3 weeks after being given one dose of doxorubicin (30 mg/m2 intravenously). The administration of doxorubicin to control dogs resulted in a significant (P < .05) decrease in T-CH, LDL-CH, and HDL-CH, as well as a significant increase in VLDL-TG and HDL-TG. When compared with untreated controls, untreated dogs with lymphoma had significantly higher concentrations of VLDL-CH, T-TG, VLDL-TG, LDL-TG, and HDL-TG, and significantly lower concentrations of HDL-CH. HDL-TG and VLDL-TG concentrations from dogs with lymphoma were significantly increased above pretreatment values after relapse and development of overt signs of cancer cachexia.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Ft Collins 80523.
authors.forename: G K
authors.initials: GK
authors.lastname: Ogilvie
authors.forename: R B
authors.initials: RB
authors.lastname: Ford
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
authors.forename: L M
authors.initials: LM
authors.lastname: Walters
authors.forename: M D
authors.initials: MD
authors.lastname: Salman
authors.forename: C
authors.initials: C
authors.lastname: Babineau
authors.forename: M J
authors.initials: MJ
authors.lastname: Fettman
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D012074:Remission Induction
chemical_list: D008074:Lipoproteins; D004317:Doxorubicin